title: A Review of Brodalumab, an IL-17 Receptor Antagonist, for Moderate-to-Severe Plaque Psoriasis.
abstract: Psoriasis is a chronic immune-mediated inflammatory disease with epidermal hyperplasia that affects 2-3% of the population. Interleukin (IL)-17 signaling has a central role in its pathogenesis. Brodalumab is a monoclonal antibody that neutralizes IL-17 receptor type A. Brodalumab is highly effective in the reversal of psoriatic phenotype and gene expression patterns.
authors.affiliation: Center for Clinical Studies, Houston, TX, USA; Department of Dermatology, University of California San Diego, La Jolla, CA, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Tong
authors.affiliation: Center for Clinical Studies, Houston, TX, USA.
authors.forename: A J
authors.initials: AJ
authors.lastname: Peranteau
authors.affiliation: Center for Clinical Studies, Houston, TX, USA; Department of Dermatology, The University of Texas Health Science Center at Houston, Houston, TX, USA.
authors.forename: Z
authors.initials: Z
authors.lastname: Nawas
authors.affiliation: Center for Clinical Studies, Houston, TX, USA; Department of Dermatology, The University of Texas Health Science Center at Houston, Houston, TX, USA.
authors.forename: S K
authors.initials: SK
authors.lastname: Tyring
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents / Q000627:therapeutic use*; D006801:Humans; D020381:Interleukin-17 / Q000502:physiology; D011565:Psoriasis / Q000188:drug therapy* / Q000503:physiopathology; D053722:Receptors, Interleukin-17 / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D020381:Interleukin-17; D053722:Receptors, Interleukin-17; C571216:brodalumab